Is Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination or Nirsevimab Prophylaxis cost-effective for preventing RSV-associated disease in Japanese infants?
Japanese infants
Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination (RSVpreF) and Nirsevimab Prophylaxis
Cost-effectiveness (Quality-Adjusted Life Years / QALY)
Seasonal RSVpreF vaccination is a cost-effective strategy for preventing RSV-associated disease in Japanese infants at a threshold of US$33,333 per QALY.
Only seasonal RSVpreF strategy is cost-effective under the JPY5 000 000/US33 333 per QALY willingness-to-pay threshold.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hoshi et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69a76663badf0bb9e87dcd07 — DOI: https://doi.org/10.1016/j.jval.2026.01.010
Shu-Ling Hoshi
Xerxes Seposo
Masahide Kondo
Value in Health
Hokkaido University
University of Tsukuba
Tsukuba University of Technology
Building similarity graph...
Analyzing shared references across papers
Loading...